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Stathmin (Sobel et al, 1989), also referred to as metablastin
(Schubart et al, 1992), p19 (Pasmantier et al, 1986), prosolin
(Cooper et al, 1989), p18 (Hanash et al, 1988), pp20 (Peyron et al,
1989) and Op18 (Hailat et al, 1990), is a small ubiquitous
cytosolic phosphoprotein, proposed to be a relay integrating
diverse cell signalling pathways (Sobel, 1991), as it is phosphoryl-
ated in parallel to the triggering of intracellular molecular cascades
by hormones (Beretta et al, 1988, 1989; Sobel and Tashjian, 1983),
growth factors (Doye et al, 1990) and neurotransmitters
(Chneiweiss et al, 1992), and because it interacts with putative
downstream protein partners including tubulin (Maucuer et al,
1995, 1997; Belmont and Mitchison, 1996; Curmi et al., 1997). A
great deal of progress has recently been made in understanding the
functions of stathmin, and it now appears that it may be one of the
key regulators of the cell division through its influence on micro-
tubule dynamics (Belmont and Mitchison, 1996; Marklund et al,
1996; Melander Gradin et al, 1997). Stathmin interacts with and
sequesters free tubulin (Curmi et al, 1997; Jourdain et al, 1997)
leading to the depolymerization of microtubules both in vitro and
in vivo. Furthermore, phosphorylation of stathmin dramatically
reduces its affinity for tubulin and thus its microtubule depolymer-
ization potential (Marklund et al, 1996; Horwitz et al, 1997;
Melander Gradin et al, 1997, 1998; Curmi
et al, 1997; Di Paolo et al, 1997; Jourdain et al, 1997; Larsson et al,
1997; Gavet et al, 1998). The modulation of stathmin activity
towards microtubules by phosphorylation is of the uttermost
interest as it is known that stathmin is sequentially phosphorylated
during the cell cycle, presumably through the concerted activity of
different kinases, leading to an extensive phosphorylation of
stathmin during mitosis (Strahler et al, 1992; Brattsand et al, 1994;
Luo et al, 1994; Gavet et al, 1998) followed by a rapid dephos-
phorylation at cytokinesis (Gavet et al, 1998). Furthermore, the
extensive phosphorylation of stathmin at mitosis seems to be
required for cell cycle progression, as suggested by the cell cycle
blockade at G2/M observed after cell transfection with various
non-phosphorylatable stathmin mutants (Marklund et al, 1994;
Larsson et al, 1995; Lawler et al, 1998).
With all these properties, stathmin appears thus as a good candi-
date for being implicated in cellular transformation or in cancer. In
fact, we recently established that stathmin was overexpressed, at
the mRNA and protein levels, in a significant proportion of human
breast cancer that may define a new breast cancer subtype (Bièche
et al, 1998). Overexpression of stathmin has also been reported in
other types of malignancies such as acute leukaemia (Hanash et al,
1988; Brattsand et al, 1993; Ghosh et al, 1993; Luo et al, 1994;
Melhem et al, 1997), lymphomas (Brattsand et al, 1993; Ghosh
et al, 1993; Nylander et al, 1995), various carcinomas (Ghosh et al,
1993) and neuroblastomas (Hailat et al, 1990).
To this day, however, the significance of stathmin overexpres-
sion in cancer remains unclear. In particular, association with the
standard prognostic markers has either not been searched for, or
when studied no correlation has been really established mainly due
to the rather small size of the series studied.
The aim of the present work was therefore to progress in the
understanding of the significance and consequences of stathmin
overexpression in cancer. We quantified by competitive reverse
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transcriptase polymerase chain reaction (RT-PCR) the amount of
stathmin mRNA in a large series (n = 133) of unilateral invasive
primary breast tumour samples, obtained in strictly followed up
women whose clinico-pathological data were fully available. We
then searched for potential correlation of stathmin overexpression
with standard prognostic factors, and examined whether alter-
ations in stathmin expression is associated with loss of hetero-
zygosity (LOH) at the stathmin locus.
MATERIALS AND METHODS
Patients’ characteristics and samples
We analysed tissue from excised primary breast tumour samples
from a series of 133 women, collected between 1977 and 1989 at
the Centre René Huguenin (St-Cloud, France). The samples were
first examined histologically for the presence of tumour cells, a
tumour sample being considered suitable for further analysis if the
proportion of tumour cells was more than 60%. Immediately after
surgical removal, the tumour samples were snap-frozen and stored
in liquid nitrogen until the time of extraction of RNA and high-
molecular-weight DNA.
Peripheral blood from the same patients was also obtained and
leucocytes were used as a source of patient’s normal DNA for
comparison.
Patient and tumour details included in the present study are
listed in Table 1, showing these to be a typically representative
cohort of breast cancer patients. Patients met the following
criteria: primary unilateral non-metastatic breast carcinoma; the
mean age was 57 years (range 34–86); complete clinical, histo-
logical and biological data; no radiotherapy or chemotherapy
before surgery. The median follow-up of these patients was long,
i.e. 9 years (range 1.0–16.2). Forty-eight patients relapsed during
the follow-up period (15 local and/or regional recurrences,
29 metastases and four patients with both were the first relapse
events). Two second invasive cancers occurred (not considered as
relapse events).
The control RNAs assayed were from seven uninvolved breast
tissue adjacent to carcinoma, and eight normal breast tissue
collected from reduction mammoplasties. To these, we added
RNA derived from a pool of six normal human breast tissues
purchased at Clontech (Cat. no. 64037–1). All these RNAs are
referred to as normal.
Evaluation of ‘classical’ prognostic factors
Histological typing was established at the time of surgery
according to the Bloom and Richardson classification (Bloom and
Richardson, 1957). Oestrogen and progesterone receptors content
of the tumours was assayed according to the guidelines of the
European Organisation for Research and Treatment for Cancer
(EORTC Breast Cooperative Group, 1980), with a detection
threshold of 10 fmol mg–1 cytosolic protein.
RNA analysis
RNA extraction and cDNA synthesis
Total RNA was extracted from pulverized frozen breast tissues by
using the acid–guanidinium thiocyanate–phenol–chloroform
method (Chomczynski and Sacchi, 1987). Quality and purity of
RNA were assessed by electrophoresis on 1.2% agarose gels.
Efficiency of recovery was calculated on an aliquot by deter-
mining the A260.
Reverse transcription was performed on 1 mg of total RNA in a
final volume of 20 ml. The reaction tube contained 2.5 mM random
hexamers, 20 units of RNAase inhibitor, and 50 units of Moloney
Murine Leukaemia Virus reverse transcriptase (Perkin-Elmer
Applied Biosystems) in a 13 RT-PCR buffer (1 mM each dNTP,
5m M magnesium chloride (MgCl2) 50 mM potassium chloride
(KCl), 10 mM Tris–HCl pH 8.3 at 25°C). After 10 min of incuba-
tion at 20°C, and 30 min at 42°C, the reverse transcriptase was
inactivated by heating at 99°C for 5 min, and the cDNA was
quickly chilled on ice to 5°C. The volume of the reaction mixture
was then brought to 200 ml with 13 RT-PCR buffer, giving the
‘RT-mix’ used for subsequent PCR.
PCR primers
Primer pairs for PCR were designed with the assistance of the
Oligo 4.0 computer program (National Biosciences, Plymouth,
MN, USA) and selected after performing BLASTN searches
against nr (All Non-redundant GenBank+EMBL+DDBJ+PDB
sequences (but no EST, STS, GSS, or HTGS sequences)) and
dbEST to confirm the total gene specificity of the primer
sequences and the absence of polymorphism. Primers are desig-
nated by the nucleotide position corresponding to the 5¢ position
(relative to stathmin GenBank no. X53305 and TBP GenBank no.
X54993), with the letter U for upper (sense strand) or L for lower
(antisense strand). Primers were 6U: 5¢ F-CTCGGACT-
GAGCAGGACTTTC 3¢ and 172L: 5¢ ATTCTTTTGACC-
Table 1 Distribution of clinical and biological parameters in a series of 133
patients with breast carcinoma. Relation to disease-free survival
Disease-free survival
Variable n (%) Number of eventsa P-valueb
Age (years)
≤50 43 (32) 13 NS
>50 90 (68) 35
Menopausal status
Premenopausal 49 (37) 17 NS
Post-menopausal 84 (63) 31
Histological gradec,d
I 18 (15) 5
II 61 (49) 26 NS
III 45 (36) 16
Nodal status
0 48 (36) 9
1–3 54 (41) 25 P < 0.05
>3 31 (23) 14
ER status
+ 90 (68) 35 NS
– 43 (32) 13
PR status
+ 79 (59) 29 NS
– 54 (41) 19
Tumour sizee
≤ 30 mm 93 (74) 32 NS
> 30 mm 33 (26) 14
aFirst relapses (local and/or regional recurrences, and/or metastases), or
breast cancer-related death without apparent relapses. bLog-rank test. cScarff
Bloom Richardson classification. dInformation available for 124 patients.
eInformation available for 126 patients. ER, oestrogen receptors; PR,
progesterone receptors (cut-off for ER and PR, 10 fm mg–1); n: number of
patients; NS: not significant.144 PA Curmi et al
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GAGGGCTG 3¢ for the stathmin gene; and 750U: 5¢ F-ACA-
GGAGCCAAGAGTGAAGAA 3¢ and 1009L: 5¢ CCAGAAA-
CAAAAATAAGGAGA 3¢ for the TBP gene (F: fluorescein mole-
cule). These primers gave a PCR product of 167 bp after 30 PCR
cycles for the stathmin gene and 260 bp after 32 PCR cycles for
the TBP gene. To avoid amplification of contaminating genomic
DNA, one of the two primers was chosen at the junction between
two exons or in a different exon. The upper primer of stathmin
(6U) thus spanned the junction between exons 1 and 2, whereas the
lower primer (172L) was placed in exon 3. One member of each
primer pair was fluorescein-labelled at the 5¢ end with fluorescein
by the fluoro-prime method.
Quantitative analysis of stathmin mRNA by RT-PCR
Stathmin mRNA expression was quantified by RT-PCR using the
TBP transcript (TATA box Binding Protein, a major component of
the TFIID transcription factor) as an endogenous mRNA control,
and each sample was normalized on the basis of its TBP content.
TBP was chosen because no retro-pseudogenes have been found
for it (the existence of retro-pseudogenes leads to co-amplification
of contaminating genomic DNA despite the use of primers from
separate exons) and because it shows an approximately similar
abundance of transcripts to that of stathmin.
To take into account the variability of PCR efficiency, we co-
amplified, using the same pair of primers, target cDNAs (stathmin
or TBP) with a ‘quantitative DNA standard’, QDS (Foley et al,
1993). QDS for each target gene contained a 12 bp insertion, and
was generated by PCR using the ‘looped oligo’ method (Sarkar
and Bolander, 1994) as described by Lazar et al (1995). Target
cDNAs and QDS thus yielded labelled PCR products of different
sizes which were easily identified after migration on a DNA
sequencing gel. The ratio between amplified target cDNA and its
QDS was checked to be constant during exponential and non-
exponential phase of PCR, according to results of Pannetier et al
(1993). Gene mRNA amount was expressed as the ratio between
target cDNA and its corresponding QDS.
For each PCR reaction, a master mix was prepared on ice with
1.5 mM MgCl2, 50 mM KCl, 10 mM Tris–HCl pH 8.3 at 25°C,
400 nM of each primer, a known amount of the corresponding
QDS and 1 unit of AmpliTaq DNA polymerase (Perkin-Elmer
Applied Biosystems). In the control group, QDS amount was
adjusted in order to obtain similar fluorescence intensities for QDS
and the corresponding cDNA-derived PCR products. Ten
microlitres of RT-mix for each sample were added on ice to 40 ml
of the master mix. PCR consisted of an initial denaturation at 94°C
for 5 min and 30–32 cycles of 30 s at 94°C, 30 s at 60°C, 45 s at
72°C, and a final extension of 10 min at 72°C, using a Perkin-
Elmer 9600 DNA thermocycler.
PCR products were diluted tenfold and 2.5 ml diluted aliquots of
each sample were added to 2.5 ml of deionized formamide
containing 0.3 ml of molecular size markers (Genescan 500 ROX,
Perkin-Elmer Applied Biosystems). The mixtures were heat-dena-
tured and 2.5 ml aliquots were loaded on 6% polyacrylamide/8 M
urea gel and run for 6 h at 1200 V in a sequencer. The amount of
the different fragments was quantified with the Genescan® 672
Fragment Analysis software (Perkin-Elmer Applied Biosystems).
Areas of each fluorescent peak was expressed as relative fluores-
cence units (RFU), which correlates to the amount of PCR
product.
Quantification was based on the determination of the relative
amount of the stathmin target message to the TBP endogenous
control to normalize the amount and quality of total RNA. Final
results, expressed as N-fold differences in stathmin gene expres-
sion relative to TBP gene expression, termed ‘Stathmin (normal-
ized)’, were determined as follows:
Stathmin (normalized) = [stathmin/stathminQDS]/[TBP/TBPQDS]
All the results of the present work regarding stathmin mRNA
expression are therefore the stathmin normalized value.
Experiments were performed with duplicates for each data point
and the mean value was determined. Reproducibility of the quanti-
tative measurements was evaluated by conducting independent
replicate cDNA syntheses and PCR reactions.
DNA analysis
DNA was extracted from frozen tumour tissue and blood leuco-
cytes from each patient, by using standard methods (Sambrook
et al, 1989).
In order to identify all patients informative for at least one locus,
the carcinomas were screened with three polymorphic micro-
satellite DNA marker loci flanking stathmin (D1S234, D1S1676,
D1S2734). Normal DNA samples which were polymorphic at a
given locus were considered to be ‘informative’, whereas homozy-
gous were considered ‘uninformative’. Only cases of constitu-
tional heterozygosity were used in the evaluation of LOH.
Microsatellite markers were assayed by PCR amplification of
genomic DNA. PCR was run in a total volume of 50 ml, with 50 ng
of genomic DNA, 400 nM each primer, 200 mM of each dNTP, and
one unit of AmpliTaq DNA polymerase (Perkin-Elmer Applied
Biosystems) (in 1.5 mM MgCl2, 50 mM KCl, 10 mM Tris–HCl
pH 8.3 at 25°C). The annealing temperature, number of amplifica-
tion cycles and extension time were adapted for each primer set.
One microlitre of product was mixed with 3 ml of denaturing
loading buffer, heat-denatured, then 1.5 ml aliquots of each sample
were loaded on 6% polyacrylamide/7.5 M urea gels. After frac-
tionation, DNA was transferred to nylon membrane filters. The
membrane filters were hybridized overnight at 42°C with the CA
repeat 32P-labelled probe, washed, and autoradiographed at –80°C
for an appropriate period.
The signal intensity of the polymorphic alleles was evaluated by
independent visual examination by three observers and confirmed
by means of densitometry. The results of all the scanned samples
were in direct agreement with the initial visual scoring. LOH was
considered to occur when the intensity of the allele in tumour
DNA was less than 40% of that measured in the corresponding
normal DNA (peripheral blood lymphocytes). LOH was partial in
most cases, the band being fainter than the conserved allele but
still visible. Such partial losses are due either to contaminating
normal tissue or to tumour heterogeneity.
Statistical analysis
Disease-free survival (DFS) was determined as the interval
between diagnosis and detection of the first relapses (local and/or
regional recurrences, and/or metastases), or breast cancer-related
death without apparent relapses.
Clinical, histological and biological parameters were compared
using the c2 test. Differences between the two populations
were judged significant at confidence levels greater than 95%
(P < 0.05). Survival distributions were estimated by the
Kaplan–Meier method (Kaplan and Meier, 1958), and theStathmin points to high mitotic index 145
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Figure 1 Expression of stathmin mRNA in control tissues and breast carcinomas, quantified by RT-PCR. (A) Scattergram showing stathmin expression obtained from either normal
breast RNA or breast cancer biopsies as described in Patients and Methods. Stathmin expression in control samples varied between 0.5 and 3.1 (mean 1.63 ± 0.84). The stathmin
overexpression threshold was calculated to 4. In the cancer sample an overexpressing subgroup of 29 tumours (21.8%) was clearly distinguishable (range 4.2–21.7; mean 7.04 ± 3.58).
(B) Scattergram showing stathmin expression in breast cancer and its distribution in the three SBR grading groups. A significant correlation was found between stathmin expression and
grade III disease (P = 0.002). (C) Scattergram showing stathmin expression in breast cancer and its distribution for the three mitotic index scores. A significant correlation was found
between stathmin expression and score 3 of the mitotic index (P = 0.02). *Information was not available for the tumour with a 21.7 stathmin expression level reported in (A)
C146 PA Curmi et al
British Journal of Cancer (2000) 82(1), 142–150 © 2000 Cancer Research Campaign
significance of differences between survival rates was ascertained
using the log-rank test (Peto et al, 1977).
RESULTS
In order to assess the significance of stathmin overexpression in
breast cancer, we evaluated the correlation of stathmin expression,
quantified by means of RT-PCR analysis, with several disease
parameters in a large series of human primary breast cancer
obtained in strictly followed up women whose clinico-
pathological data were fully available (Table 1).
Expression of stathmin mRNA in breast tissues
Stathmin mRNA expression in normal (n = 16) or breast cancer
specimens (n = 133) was determined by RT-PCR. The results were
standardized by comparison with the mRNA level of an endoge-
nous mRNA control to give the stathmin mRNA normalized value
(see Patients and Methods). The stathmin mRNA expression
values reported in this paper are therefore the normalized stathmin
mRNA values.
Stathmin mRNA expression was first assessed for the control
normal breast RNAs. Expression levels varied between 0.5 and 3.1
(mean 1.63 ± s.d. 0.84) (Figure 1A). From these values, we deter-
mined the cut-off for altered stathmin mRNA expression in breast
cancer as the mean value ± 3 s.d. observed for the control normal
breast mRNA. Stathmin mRNA was thus considered to be over-
expressed for expression values ³ 4.
Stathmin mRNA expression was next quantified in the breast
cancer samples (n = 133). Levels of stathmin varied between 0.5
and 21.7 (Figure 1A). Using the stathmin overexpression cut-off
value of 4, we classified tumours in two stathmin expression
groups, basal and overexpression. In the basal group (n = 104), the
mean value of stathmin mRNA expression was equal to 1.65 ± 0.7
(range 0.5–3.8) a value not distinguishable from that found in the
control normal group. In the overexpression group (n = 29) the
mean value of stathmin mRNA expression was equal to
7.04  ± 3.58 (range 4.2–21.7). Stathmin expression thus varied in
this group between 2.6 and 13.3 times the mean control value.
An example of tumours in which the expression level was
basal (STAT no. 37, stathmin = 2.2) and high (STAT no. 86,
stathmin = 7.1) is presented in Figure 2.
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Figure 2 RT-PCR analysis of the stathmin mRNA content of two breast tumour samples. Peaks stathmin (or TBP) and stathminQDS (or TBPQDS) represent the
PCR products of the stathmin cDNA (or TBP) and of its corresponding QDS. The area of each peak correlates with the amount of PCR product. For each
tumour sample, the stathmin cDNA peak area value (Sta) was divided by the stathmin QDS peak area value (StaQDS) to obtain a stathmin mRNA amount
value (Sta/StaQDS) which was next divided by the TBP mRNA amount value (TBP/TBPQDS) to obtain the final stathmin (normalized) value. Duplicate analysis
for each tumour sample were performed (a single is shown here). The stathmin (normalized) value was equal to 2.2 in tumour STAT no. 37 and 7.1 in tumour
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Correlation of stathmin mRNA expression in breast
cancers with standard prognostic factors
We sought links between stathmin mRNA level status and stan-
dard clinico-pathological and biological factors in breast cancer
(Table 2). Interestingly, stathmin overexpression was significantly
correlated with a number of parameters known to be associated
with poor prognosis. Overexpression was correlated with grade III
disease (P = 0.002) (Table 2 and Figure 1B), loss of oestrogen
receptor (P = 0.0006) or progesterone receptor (P = 0.008). In the
SBR grading, three morphological features (tubular formation,
nuclear pleomorphism and mitotic index) were scored from 1 to 3.
When we tested stathmin mRNA expression with regard to these
three components (Table 3), it appears that the association of
stathmin overexpression with SBR grade III was essentially due to
the mitotic index (P = 0.02) (Figure 1B, C).
These results indicate that overexpression of stathmin is associ-
ated with highly proliferative primary breast carcinoma showing
signs of aggressiveness. However, it is interesting to note that no
association was observed with axillary lymph node. Moreover,
patients with tumours overexpressing stathmin did not relapse
more frequently (Table 2) and did not have significantly shorter
disease-free survival after surgery compared to patients with
tumours showing basal level of stathmin expression (log-rank
test).
Relationship between the stathmin mRNA levels and
1p36.1 LOH
Assessment of LOH (loss of heterozygosity) with three polymor-
phic DNA markers (D1S234, D1S1676, D1S2734) encompassing
1 cM in 1p36.1 and flanking the stathmin gene (Jensen et al, 1997)
is shown in Table 4. 116 of the 133 tumours studied for stathmin
expression were tested for LOH. Of these, 112 patients were infor-
mative for one or more loci on 1p36.1. LOH was found in 29.5%
(33/112) of the informative tumour DNAs, while the remainder
had a normal profile. As shown in Table 4, we found no link
between stathmin LOH and stathmin mRNA overexpression indi-
cating that deletion of the stathmin gene or of the region encom-
passing it may not be the cause of its overexpression.
DISCUSSION
We recently demonstrated that stathmin was overexpressed, at the
mRNA and protein levels, in a significant proportion of human
breast cancers (about 30%) that may define a new breast cancer
subtype (Bièche et al, 1998). In this pilot study, we found essen-
tially no significant correlation between stathmin overexpression
and any of the classical prognostic parameters because the sample
Table 2 Association between stathmin mRNA expression and the different
prognostic criteria
Stathmin mRNA
Basal Overexpression
Variable n (%) n (%) n (%) P-valuea
Total 133 (100) 104 (78) 29 (22)
Age (years)
≤50 43 (32) 34 (33) 9 (31) NS
>50 90 (68) 70 (67) 20 (69)
Menopausal status
Premenopausal 49 (37) 39 (37) 10 (34) NS
Post-menopausal 84 (63) 65 (63) 19 (66)
Histological gradeb,c
I 18 (15) 17 (17) 1 (4) 0.002
II 61 (49) 53 (54) 8 (31)
III 45 (36) 28 (29) 17 (65)
Nodal status
0 48 (36) 34 (33) 14 (48) NS
1–3 54 (41) 45 (43) 9 (31)
>4 31 (23) 25 (24) 6 (21)
ER status
+ 90 (68) 78 (75) 12 (41) 0.0006
– 43 (32) 26 (25) 17 (59)
PR status
+ 79 (59) 68 (65) 11 (38) 0.008
– 54 (41) 36 (35) 18 (62)
Tumour sized
≤30 mm 93 (74) 74 (75) 19 (70) NS
>30 mm 33 (26) 25 (25) 8 (30)
Relapses
+ 48 (36) 40 (38) 8 (28) NS
– 85 (64) 64 (62) 21 (72)
aChi-square test. bScarff–Bloom–Richardson classification. cInformation
available for 124 patients. dInformation available for 126 patients. ER,
oestrogen receptors; PR, progesterone receptors (cut-off for ER and PR,
10 fm mg–1); n: number of patients; NS: not significant
Table 3 Association between stathmin mRNA expression and the SBR
histopathological grade components
Stathmin mRNA
Basal Overexpression
n (%) n (%) n (%) P-valuea
Total 124 (100) 98 (79) 26 (21)
Tubular differentiation
I 5 (4) 4 (4) 1 (4)
II 80 (65) 68 (69) 12 (46) NS
III 39 (31) 26 (27) 13 (50)
Nuclear polymorphism
I 7 (6) 7 (7) 0
II 84 (68) 68 (69) 16 (62) NS
III 33 (26) 23 (24) 10 (38)
Mitotic index
I 16 (13) 16 (16) 0
II 30 (24) 26 (27) 4 (15) 0.02
III 78 (63) 56 (57) 22 (85)
aChi-square test with Yates’ correction. n: number of patients, NS: not
significant.
Table 4 Association between stathmin DNA status and stathmin mRNA
expressiona
Stathmin mRNA
Total population Basal Overexpression
n (%) n (%) n (%)
1p36 Yes 33(29) 24(28) 9(33)
LOH No 79(71) 61(72) 18(67) NS
aFrequency of chromosome 1p36.1 alteration as determined with the
D1S234, D1S1676 and D1S2734 markers: alteration in breast tumours and
association with stathmin mRNA overexpression. n: number of patients,
NS: not significant.148 PA Curmi et al
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size (n = 50) was too small to attempt reasonable statistical corre-
lation. The aim of the present work was thus to evaluate the prog-
nostic significance of stathmin overexpression, quantified with a
competitive RT-PCR-based strategy, in a larger population of
human breast cancer (n = 133) for which clinico-pathological data
were fully available. Our analyses of stathmin expression were
restricted to mRNA because we showed previously that a perfect
match existed, in breast cancer, between stathmin mRNA and
protein expression (appreciated by Western blotting and immuno-
histochemistry), suggesting that no post-transcriptional regulation
occurred for stathmin.
First of all our results allowed us to refine the data obtained in
our initial survey. We definitely confirmed the existence of two
statistically different populations (or groups) of breast cancers in
view of stathmin expression: a basal group whose expression level
was indistinguishable from non tumoural breast samples consid-
ered as control, and an overexpressing group in which stathmin
expression levels were quite higher. The level of stathmin mRNA
in the overexpression group varied between 2.6 and 13.3 times
(mean 4.26) that found in the basal group. This result is in good
agreement with the mRNA values estimated by means of Northern
blot in our initial work. With our new data set, the percentage of
breast cancers that overexpress stathmin was adjusted to about
22%, a value again not far from the 30% reported in the previous
study, but which reflects with a better accuracy the real extent of
this population. Finally our present analysis allows to restrict the
hypotheses about the mechanism(s) of stathmin overexpression in
view of the lack of actually significant correlation between
stathmin overexpression and 1p36.1 LOH. This result clearly rules
out the possibility that overexpression may be related to a deletion
in the region of the stathmin gene.
Analysis of the data for association between stathmin over-
expression and a number of disease parameters revealed that
stathmin overexpression is significantly correlated to some
parameters known to be associated with poor prognosis.
Overexpression is correlated with grade III disease, and loss of
oestrogen or progesterone receptors. While the SBR grade III
correlation is of interest, we show further that it is due to a signifi-
cant relationship between overexpression of stathmin and the score
3 of the mitotic index, one of the three components of the SBR
grading. Overexpression of stathmin thus amazingly points out to
highly proliferative primary breast carcinomas showing signs of
aggressiveness, although no association was observed with axil-
lary lymph node and stathmin mRNA overexpression is not a
predictor for a shorter disease-free survival.
Stathmin overexpression has already been observed in different
types of cancers but, except for the work of Friedrich et al
conducted on a limited number of human prostatic carcinomas
(n = 40) (Friedrich et al, 1995), has not been correlated to human
clinico-pathological parameters. Thus, to the best of our knowl-
edge, our work is the first that reports an evaluation of stathmin
expression in such a large series of human cancer allowing clear
statistical analysis. Our results raise questions that need to be
clarified:
1. Does stathmin overexpression contribute to tumorigenesis?
Experimental data from our laboratory (Koppel et al, 1993;
Balogh et al, 1996) indicate that stathmin expression is up-
regulated at a stage that precedes cell differentiation in relation
to the limitation of cell overgrowth. We could thus envision
that overexpression of stathmin may be part of a regulatory
loop aimed at counteracting cell proliferation, although
inefficiently in cancer cells.
2. What are the mechanisms which may have led to stathmin
overexpression? Our data indicate that stathmin overexpres-
sion may be related to an increased transcription or to a
messenger stabilization. The analysis of the 5¢-flanking
sequences of the stathmin gene (Melhem et al, 1991) has
revealed the presence of several transcription factor recogni-
tion sequences: two AP-2 sites, five GC boxes which fit the
Sp1 consensus recognition sequences and four E2F sites. AP 2
family may participate to the well known overexpression of
the proto-oncogene c-erbB 2 observed in about 25–30% of the
breast cancers (Slamon et al, 1989). In parallel to the present
study, c-erbB-2 was quantified by RT-PCR in our series of
tumours (Bièche et al, 1999) and no
association was noted between stathmin and c-erbB-2 over-
expression. Sp1 recognizes GC box sequences in a number of
cellular and viral promoters (Kadonaga et al, 1997), and is
essential for transcription from TATA-less promoters (Pugh
and Tjian, 1990, 1991) which is the case of the stathmin gene
(Melhem et al, 1991). An increase in Sp1 transcription or a
stabilization of the Sp1 protein by a post-translational
modification such as glycosylation (Han and Kudlow, 1997)
could thus be conceivable for being the cause of a stathmin
over-transcription. On the other hand, E2F is probably not
involved since it has been shown that overexpression of
members of the E2F family induced apoptosis in human breast
cancer cell lines (Hunt et al, 1997) while its blocking, in
contrast, inhibits apoptosis (Bargou et al, 1996).
3. Another point raised by our work is to understand the reasons
of the apparent inefficiency of stathmin to block or to slow
down the cell cycle. Knowing the dramatic effects of stathmin
toward microtubule depolymerization in vitro (Belmont and
Mitchison, 1996; Horwitz et al, 1997; Jourdain et al, 1997) and
in vivo (Gavet et al, 1998), as well as its ability to counteract
the cell cycle (Marklund et al, 1994; Larsson et al, 1995;
Lawler et al, 1998), the coexistence of a high mitotic index
with stathmin overexpression is particularly amazing.
Different hypotheses can be proposed to account for this
apparent contradiction: (i) a novel equilibrium is reached
between stathmin and tubulin due to a compensatory increase
in the overall cellular content of tubulin; (ii) the
stathmin–tubulin interaction is altered. However the stathmin
side seems not to be affected since the protein migrates at the
right place on two-dimensional PAGE (Hailat et al, 1990;
Bièche et al, 1998); we thus cannot exclude that some sort of
tubulin alteration or third partner could impair the
stathmin–tubulin interaction; (iii) stathmin is massively phos-
phorylated and thus rendered inactive in mitosis. Data already
published on stathmin phosphorylation in tumours, including
ours, indicate that apparently it is poorly phosphorylated.
In conclusion, we demonstrated that stathmin is overexpressed,
by increased transcription or mRNA stabilization, in about 22% of
human primary breast tumours and points out to highly prolifera-
tive primary breast carcinomas showing signs of aggressiveness.
Our results are in an apparent contradiction with the current
knowledge of the stathmin anti-proliferative potential and raise
questions regarding the causes of its overexpression and, more
importantly, the reasons of its inability to counteract cellular
proliferation. The existence of a stathmin overexpressing group inhuman breast carcinomas offers a new target for drug or gene
therapy directed toward the disturbance of the stathmin–tubulin
equilibrium which should block the cell cycle, as data obtained
from cellular transfections with antisense (Luo et al, 1994) or
sense non-phosphorylatable stathmin (Marklund et al, 1994; Gavet
et al, 1998; Lawler et al, 1998) indicate that any acute change of
the stathmin–tubulin equilibrium should lead to a substantial cell
cycle inhibition.
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